These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 9412672)

  • 1. Efficacy of low dosages of epoetin alfa in dogs.
    Allen AG
    J Am Vet Med Assoc; 1997 Dec; 211(12):1504-5. PubMed ID: 9412672
    [No Abstract]   [Full Text] [Related]  

  • 2. Relative mortality and epoetin alpha dose among hemodialysis patients.
    Coyne DW
    Am J Kidney Dis; 2008 May; 51(5):866-7; author reply 867. PubMed ID: 18436101
    [No Abstract]   [Full Text] [Related]  

  • 3. Relative mortality and epoetin alpha dose in hemodialysis patients.
    Cotter DJ; Thamer M; Zhang Y
    Am J Kidney Dis; 2008 May; 51(5):865; author reply 865-6. PubMed ID: 18436099
    [No Abstract]   [Full Text] [Related]  

  • 4. Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes.
    Collins AJ; Brenner RM; Ofman JJ; Chi EM; Stuccio-White N; Krishnan M; Solid C; Ofsthun NJ; Lazarus JM
    Am J Kidney Dis; 2005 Sep; 46(3):481-8. PubMed ID: 16129210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients.
    Rossert J; Gassmann-Mayer C; Frei D; McClellan W
    Nephrol Dial Transplant; 2007 Mar; 22(3):794-800. PubMed ID: 17210593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure.
    Cowgill LD; James KM; Levy JK; Browne JK; Miller A; Lobingier RT; Egrie JC
    J Am Vet Med Assoc; 1998 Feb; 212(4):521-8. PubMed ID: 9491159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison between once-weekly and twice- or thrice-weekly subcutaneous injection of epoetin alfa: results from a randomized controlled multicentre study.
    Lee YK; Kim SG; Seo JW; Oh JE; Yoon JW; Koo JR; Kim HJ; Noh JW
    Nephrol Dial Transplant; 2008 Oct; 23(10):3240-6. PubMed ID: 18469158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anemia and response to epoetin alfa: the cause of anemia matters!
    Dharmarajan TS
    J Am Geriatr Soc; 2008 Aug; 56(8):1574-5. PubMed ID: 18808607
    [No Abstract]   [Full Text] [Related]  

  • 10. Once-weekly erythropoietic therapy: is there a difference between the available preparations?
    Weiss LG
    Nephrol Dial Transplant; 2004 May; 19(5):1330-1; author reply 1331. PubMed ID: 15102981
    [No Abstract]   [Full Text] [Related]  

  • 11. TlpTLE: epotin and pure red-cell aplasia: what do we have?
    Massimo G; Daria M; Giorgina PB; Alberto J
    Med Sci Monit; 2003 Jul; 9(7):LE18. PubMed ID: 12956116
    [No Abstract]   [Full Text] [Related]  

  • 12. Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review.
    Germain M; Ram CV; Bhaduri S; Tang KL; Klausner M; Curzi M
    Nephrol Dial Transplant; 2005 Oct; 20(10):2146-52. PubMed ID: 15985516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epoetin delta is effective for the management of anaemia associated with chronic kidney disease.
    Spinowitz BS; Pratt RD;
    Curr Med Res Opin; 2006 Dec; 22(12):2507-13. PubMed ID: 17166333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa.
    Dieterich DT; Wasserman R; Bräu N; Hassanein TI; Bini EJ; Bowers PJ; Sulkowski MS
    Am J Gastroenterol; 2003 Nov; 98(11):2491-9. PubMed ID: 14638354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is early treatment of anaemia with epoetin-alpha beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial.
    Macdougall IC; Temple RM; Kwan JT
    Nephrol Dial Transplant; 2007 Mar; 22(3):784-93. PubMed ID: 16968726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose of epoetin alfa used in haemodialysis patients when switching from subcutaneous to intravenous administration.
    Pussell BA; Walker R
    Nephrology (Carlton); 2007 Apr; 12(2):120-5. PubMed ID: 17371332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and future challenges in anaemia management.
    Levin A; Locatelli F; Muirhead N; Ritz E
    Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi1-2. PubMed ID: 15958819
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epoetin alfa as a supportive measure in hematologic malignancies.
    Straus DJ
    Semin Hematol; 2002 Oct; 39(4 Suppl 3):25-31. PubMed ID: 12447849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ascorbic acid use in hyporesponders to Epoetin alfa.
    Gibbs MA
    Nephrol Nurs J; 2000 Aug; 27(4):413-5. PubMed ID: 11276634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.